Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity

Daniel J. Cuthbertson*, John Babraj, Graham Leese, Mario Siervo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
96 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity'. Together they form a unique fingerprint.

Medicine & Life Sciences